FATE Stock Cash Flow Statements

Fate Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Fate Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31

operating activities
net income	-34,070,000	-37,621,000	-52,153,000	-47,678,000	-38,427,000	-48,004,000	-44,122,000	-45,170,000	-52,755,000	-18,881,000	-56,363,000	-83,563,000	-76,105,000	-65,690,000	-68,621,000	-43,308,000	-55,133,000	-45,089,000	-53,111,000	-58,684,000	-28,072,000	-33,520,000	-28,302,000	-26,609,000	-23,478,000	-19,760,000	-16,027,000	-16,782,000	-19,654,000	-14,135,000	-12,497,000	-10,684,000	-9,645,000	-10,126,000	-7,940,000	-8,737,000	-8,408,000	-8,377,000	-7,446,000	-6,886,000	-7,779,000	-7,881,000	-6,603,000	-6,067,000	-6,980,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	3,278,000	3,333,000	4,813,000	4,607,000	4,721,000	4,821,000	4,885,000	4,740,000	4,466,000	4,191,000	4,842,000	3,193,000	2,962,000	2,761,000	2,206,000	1,519,000	1,166,000	959,000	861,000	773,000	748,000	705,000	623,000	587,000	543,000	440,000	327,000	310,000	281,000	286,000	290,000	244,000	231,000	206,000	203,000	218,000	233,000	227,000	210,000	187,000	162,000	128,000	115,000	133,000	123,000
stock-based compensation	7,154,000	7,381,000		11,765,000	9,630,000	10,981,000		10,104,000	12,897,000	10,983,000		19,468,000	20,542,000	19,331,000		13,540,000	13,254,000	12,976,000		7,843,000	7,236,000	6,913,000		4,573,000	4,386,000	3,868,000		1,642,000	1,485,000	1,382,000		871,000	973,000	867,000		782,000	786,000	797,000		574,000	738,000	608,000	527,000	424,000	871,000
accretion and amortization of premiums and discounts on investments	-847,000	-1,068,000	-1,530,000	-2,196,000	-2,723,000	-2,631,000	-2,906,000	-3,257,000	-2,940,000	-2,295,000	-1,245,000	-409,000	525,000	873,000	1,072,000	1,366,000	1,489,000	1,140,000	855,000	303,000	247,000	271,000	80,000
deferred revenue	-212,000	-181,000	-207,000	0	-160,000	-525,000	-425,000	-820,000	192,000	-40,488,000	-5,422,000	-3,752,000	6,290,000	-3,497,000	-7,502,000	-5,849,000	-2,101,000	-3,107,000	666,000	-2,816,000	63,268,000	-515,000	-1,301,000	-2,430,000	-2,663,000	-2,132,000	3,838,000	9,474,000	-527,000	-526,000	-526,000	-526,000	-527,000	-526,000	-526,000	-526,000	-527,000	-822,000	-576,000	-180,000
change in fair value of stock price appreciation milestones	73,000	-280,000	-670,000	13,000	-1,556,000	1,394,000	645,000	-1,049,000	-393,000	-1,718,000	-5,176,000	-891,000	-5,881,000	-8,359,000	-464,000	-11,026,000	8,700,000	-744,000	20,058,000
loss on disposal of property and equipment			0
changes in operating assets and liabilities:
accounts receivable	1,010,000	1,134,000	588,000	-2,479,000	-190,000	968,000	-288,000	1,296,000	10,666,000	24,980,000	-28,257,000	2,903,000	724,000	-5,174,000	-1,365,000	2,993,000	-3,358,000	-1,430,000	-2,272,000	-1,526,000			0	0			0			-500,000
prepaid expenses and other assets	-786,000	3,925,000	-57,000	4,216,000	-3,487,000	4,565,000	-1,636,000	-1,465,000	4,076,000	11,901,000	-7,406,000	-2,788,000	-5,729,000	-2,407,000	-1,131,000	-252,000	-368,000	-1,301,000	-1,378,000	584,000	-13,424,000	636,000	-2,778,000	348,000	-273,000	792,000
accounts payable and accrued expenses	484,000	-9,826,000	655,000	1,871,000	320,000	-4,507,000	-1,893,000	-2,281,000	-4,373,000	-20,393,000	3,387,000	10,279,000	4,079,000	-3,493,000	-10,380,000	6,737,000	2,606,000	6,944,000	1,072,000	-7,430,000	8,120,000	-3,316,000	1,511,000	3,659,000	365,000	-1,258,000	336,000	1,175,000	2,070,000	673,000	1,554,000	-184,000	-536,000	1,677,000	217,000	176,000	378,000	790,000	-282,000	-97,000	587,000	269,000	228,000	-35,000	43,000
right-of-use assets and lease liabilities	-635,000	-606,000	-3,095,000	-480,000	-434,000	-412,000	-372,000	-371,000	-329,000	-336,000	-271,000	-270,000	-235,000	-52,000	11,000	-201,000	660,000	1,933,000	1,974,000	1,960,000	1,959,000	1,985,000	32,000	33,000	348,000	361,000
net cash from operating activities	-24,587,000	-33,809,000	-27,799,000	-29,419,000	-32,306,000	-33,350,000	-36,637,000	-38,273,000	-28,493,000	-28,860,000	-75,389,000	-55,047,000	-53,159,000	-64,613,000	-70,293,000	-33,375,000	-32,106,000	-27,096,000	-20,664,000	-30,733,000	38,841,000	-26,673,000	-25,535,000	-19,838,000	-20,309,000	-17,493,000	-11,020,000	-3,556,000	-11,523,000	-12,551,000	-10,721,000	-9,857,000	-8,872,000	-7,455,000	-7,551,000	-7,516,000	-7,504,000	-7,252,000
capex	-1,024,000	-541,000	26,000	-581,000	37,000	-72,000	-181,000	-1,009,000	-2,199,000	-2,596,000	-7,610,000	-8,157,000	-12,037,000	-6,707,000	-17,620,000	-12,548,000	-14,808,000	-1,357,000	-1,969,000	57,000	-807,000	-727,000	-2,792,000	-1,513,000	-2,224,000	-264,000	-1,117,000	-724,000	-278,000	-184,000	-797,000	-362,000	-411,000	-155,000	-40,000	-33,000	-206,000	-178,000
free cash flows	-25,611,000	-34,350,000	-27,773,000	-30,000,000	-32,269,000	-33,422,000	-36,818,000	-39,282,000	-30,692,000	-31,456,000	-82,999,000	-63,204,000	-65,196,000	-71,320,000	-87,913,000	-45,923,000	-46,914,000	-28,453,000	-22,633,000	-30,676,000	38,034,000	-27,400,000	-28,327,000	-21,351,000	-22,533,000	-17,757,000	-12,137,000	-4,280,000	-11,801,000	-12,735,000	-11,518,000	-10,219,000	-9,283,000	-7,610,000	-7,591,000	-7,549,000	-7,710,000	-7,430,000
investing activities
proceeds from sale of property and equipment
purchases of property and equipment	-1,362,000	-1,196,000	-98,000	-495,000	-51,000	-86,000	-181,000	-565,000	-2,199,000	-3,208,000	-6,677,000	-8,676,000	-10,129,000	-10,084,000	-18,369,000	-14,735,000	-13,619,000	-3,981,000	-2,272,000	-954,000	-636,000	-1,070,000	-2,590,000	-1,264,000	-1,795,000	-1,746,000
purchases of investments	-50,813,000	-48,624,000	-38,005,000	-64,744,000	-128,666,000	-86,335,000	-49,966,000	-102,130,000	-92,262,000	-114,452,000	-107,102,000	-101,579,000	-63,949,000	-132,166,000	-173,447,000	-165,468,000	-99,337,000	-529,907,000	-185,007,000
maturities of investments	71,644,000	92,493,000	60,919,000	90,700,000	75,344,000	103,735,000	95,500,000	127,500,000	127,628,000	127,000,000	166,891,000	190,633,000	114,365,000	135,224,000	263,094,000	258,162,000	111,584,000	62,000,000	21,250,000	39,150,000	35,956,000	24,844,000
net cash from investing activities	19,591,000	42,673,000	22,816,000	25,461,000	-53,373,000	17,314,000	45,353,000	24,805,000	33,167,000	9,340,000	53,112,000	80,378,000	40,287,000	-7,026,000	71,278,000	77,959,000	-1,372,000	-471,888,000	-166,029,000	-54,141,000	35,320,000	23,774,000	-110,516,000	36,286,000	-91,977,000	8,754,000	16,383,000	13,276,000	13,722,000	-43,844,000	13,203,000	13,638,000	1,339,000	-38,376,000	5,978,000	458,000	5,794,000	-16,344,000
financing activities
issuance of common stock from equity incentive plans, net of issuance costs			0	0	-4,000	299,000	-180,000	0	58,000	207,000	1,517,000	1,487,000	3,406,000	2,797,000	3,449,000	7,942,000	3,718,000	5,605,000	4,885,000	1,200,000	2,559,000	1,011,000		163,000	688,000	1,258,000		1,133,000	175,000	606,000		106,000	32,000	34,000		24,000	-4,000	147,000
proceeds from public offering of common stock, net of issuance costs			0	0	-662,000	75,193,000									-31,000	0			0	-270,000			-136,000																0	-143,000
proceeds from issuance of pre-funded warrants, net of issuance costs			0	0	0	19,996,000									0	0
proceeds from ft819 cirm award			3,130,000	0
proceeds from ft836 cirm award
net cash from financing activities			3,130,000	0	1,274,000	95,488,000	-180,000	0	58,000	207,000	1,517,000	1,487,000	3,406,000	2,797,000	3,418,000	7,942,000	3,719,000	438,050,000	4,910,000	930,000	275,547,000	1,451,000	-13,723,000	161,705,000	688,000	1,258,000	1,904,000				43,239,000	8,387,000	-2,012,000	-2,170,000	53,083,000	8,287,000	-1,907,000	-1,726,000	-900,000	-533,000	36,961,000	75,000
net change in cash, cash equivalents and restricted cash	-3,671,000	8,864,000	-1,853,000	-3,958,000	-84,405,000	79,452,000	8,536,000	-13,468,000	4,732,000	-19,313,000	-20,760,000	26,818,000	-9,466,000	-68,842,000	4,403,000	52,526,000	-29,759,000	-60,934,000	-181,783,000	-83,944,000	349,708,000	-1,448,000	-149,774,000	178,153,000	-111,598,000	-7,481,000	7,267,000	147,085,000	3,355,000	-56,040,000	45,721,000	12,168,000
cash, cash equivalents and restricted cash at beginning of the period	0	46,283,000		0	0	57,047,000		0	0	76,560,000		0	0	148,810,000		0	0	182,574,000	0	0	0	100,041,000	0	0	0	190,741,000	0	0	0	89,074,000	0	0
cash, cash equivalents and restricted cash at end of the period	-3,671,000	55,147,000		-3,958,000	-84,405,000	136,499,000		-13,468,000	4,732,000	57,247,000		26,818,000	-9,466,000	79,968,000		52,526,000	-29,759,000	121,640,000	-181,783,000	-83,944,000	349,708,000	98,593,000	-149,774,000	178,153,000	-111,598,000	183,260,000	7,267,000	147,085,000	3,355,000	33,034,000	45,721,000	12,168,000
supplemental schedule of noncash investing and financing activities
purchases of property and equipment in accounts payable	338,000	655,000	124,000	-86,000	88,000	14,000		-444,000	0	612,000	-933,000	519,000	-1,908,000	3,377,000	749,000	2,187,000	-1,189,000	2,624,000	303,000	1,011,000	-171,000	343,000	-202,000	-249,000	-429,000	1,482,000
accrued issuance costs included in additional paid-in-capital						558,000
operating activities:
adjustments to reconcile net income to net cash from operating activities
stock–based compensation
amortization of collaboration contract costs
impairment of long-lived assets
grant income from ft516 cirm award
changes in assets and liabilities:
cash, cash equivalents and restricted cash at beginning of the year
cash, cash equivalents and restricted cash at end of the year
amortization of collaboration contract assets								0	0	7,196,000		783,000	-331,000	1,094,000		1,106,000	979,000	623,000		616,000
right-of-use assets obtained in exchange for lease obligations
grant income from 2018 cirm award
amortization of collaboration contract asset																						168,000	187,000	162,000	164,000	107,000
grant income from cirm award							0	0	0	-4,000,000
right-of use assets obtained in exchange for lease obligations								0				164,000				0	102,000	1,444,000		-127,000	418,000	47,808,000
proceeds from private placement of common stock, net of issuance costs																			-25,000	0
proceeds from sale of common stock to collaboration partner, net of issuance costs																			0	0
proceeds from cirm award																			50,000	0	0	440,000					1,370,000	1,140,000
proceeds from public offering of common stock and issuance of pre-funded warrants, net of issuance costs																		432,445,000
amortization of debt discounts and debt issuance costs																							68,000	15,000	17,000	15,000	19,000	19,000	19,000	19,000	19,000	19,000	19,000	24,000	28,000	33,000	38,000	40,000
principal repayments of long–term debt
supplemental disclosure of cash flow information
interest paid																							1,353,000	312,000	317,000	309,000
noncash interest expense																								79,000	80,000	79,000	94,000	94,000	93,000	92,000	94,000	89,000	61,000	77,000	96,000	112,000	127,000	157,000	157,000	165,000	165,000	164,000	59,000	7,000	10,000
deferred rent																											55,000	66,000	2,000	69,000	269,000	268,000	276,000	272,000	1,000	2,000	-3,000	-7,000
issuance of common stock for license agreement
principal repayments of long-term debt
issuance on common stock for license agreement
non-cash loss on extinguishment of debt
cash payments included in loss on extinguishment of debt
issuance of common stock from equity incentive plans, net of repurchases and issuance costs																																								221,000
proceeds from private placement issuances of common stock, net of issuance costs
proceeds from private placement issuance of preferred stock, net of issuance costs
proceeds from long–term debt
payments of debt issuance costs
payments included in loss on extinguishment of debt
issuance of warrants for common stock in connection with long–term debt
purchases of short-term investments																								0			0	0	0	-55,660,000	0	0	0	-39,971,000	0	-3,509,000	0	-16,166,000
maturities of short-term investments																								37,550,000	16,000,000	10,500,000	17,500,000	14,000,000	14,000,000	12,000,000	14,000,000	14,000,000	1,750,000	1,750,000	6,000,000	4,000,000
amortization of premiums and discounts on investments																									-298,000	-5,000	-36,000	-87,000	-137,000	-75,000	-4,000	-7,000	-13,000	-1,000	13,000	41,000	62,000	55,000
issuance costs from public offering of common stock																													-19,000	-251,000
cash flows from operating activities
issuance of common stock for license agreements																											0
cash flows from investing activities
purchase of property and equipment																											-1,117,000	-724,000	-278,000	-184,000	-797,000	-362,000	-411,000	-155,000	-40,000	-33,000	-206,000	-178,000
cash flows from financing activities
proceeds from public offerings of common stock, net of issuance costs																											-245,000
payments on long–term debt
prepaid expenses and other current assets																												-222,000	-500,000	164,000		23,000	289,000	75,000		383,000	-190,000	-112,000		-87,000	72,000	303,000	164,000	52,000	304,000
issuance costs from private placement of common stock																																0	0	-65,000
issuance costs from private placement of preferred stock																																0	0	-128,000
proceeds from long-term debt
payments on long-term debt																																-6,709,000	-2,044,000	-2,011,000		-1,938,000	-1,903,000	-1,873,000
net cash provided (used) by financing activities																													1,156,000	355,000
loss on extinguishment of debt																															0
proceeds from sale of common stock to collaboration partner																																							0	0
payments for the issuance of debt
proceeds from private placement issuance of common stock, net of issuance costs
net change in cash and cash equivalents																																		-48,001,000	51,510,000	1,229,000	-3,617,000	-25,322,000	-8,048,000	-8,319,000
cash and cash equivalents at beginning of the period																																		88,609,000	0	0	0	64,809,000	0	0	0	49,101,000	0	0	54,036,000
cash and cash equivalents at end of the period																																		40,608,000	51,510,000	1,229,000	-3,617,000	39,487,000	-8,048,000	-8,319,000	38,827,000	42,349,000	3,518,000	-5,869,000	47,881,000
stock–based milestone charges and change in fair value of exchangeable shares
issuances of common stock for technology
amortization of discounts																																												6,000	8,000
change in fair value of preferred stock warrants
loss on disposal of assets
issuance of common stock, net of repurchases and issuance cost
issuance of convertible promissory notes
payment on convertible promissory note
beneficial conversion feature related to convertible notes
conversion of convertible preferred stock into common stock
conversion of convertible notes into common stock
exchange of exchangeable shares into common stock
warrant liability reclassification to equity
amortization of discounts and debt issuance costs																																								45,000	43,000	44,000
stock-based milestone charges
stock-based milestone charges and change in fair value of exchangeable shares																																											0	0	375,000
issuance of common stock, net of repurchases and issuance costs																																										75,000	2,000
proceeds from (cost of) initial public offering, net of offering costs
restricted cash
repurchase of common stock for cash
proceeds from initial public offering, net of offering costs
issuance of preferred stock for cash, net of offering costs
consolidated net income
initial fair value and change in fair value of exchangeable shares
issuance of common stock, net of repurchases
costs paid in connection with initial public offering
proceeds from convertible promissory notes
issuance of convertible preferred stock, net of offering costs

We provide you with 20 years of cash flow statements for Fate Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Fate Therapeutics stock. Explore the full financial landscape of Fate Therapeutics stock with our expertly curated income statements.

The information provided in this report about Fate Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.